REG - ReNeuron Group plc - Posting of AR and Accounts and Notice of AGM

ReNeuronAnnouncement

16/08/2021 14:20

RNS Number : 7906I
  
ReNeuron Group plc
  
16 August 2021
  
 

 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
 Posting of Annual Report and Accounts and Notice of AGM
 
ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31  March 2021 and the Notice of the 2021 Annual General Meeting ("AGM") have today been sent to shareholders and are also available on the Company's website at www.reneuron.com.
 
ReNeuron's AGM will be held at 10.00am on Thursday 16 September 2021 in the Hilton London Paddington, 146 Praed Street, London, W2 1EE.
 
At the time of publication of the notice of AGM, the Government has lifted most legal restrictions relating to public gatherings that had previously been in place due to the ongoing COVID-19 Pandemic. In line with this, the Board welcomes the opportunity to invite shareholders to attend the AGM in person. Should this situation change, shareholders will be notified though our website www.reneuron.com and, where appropriate by RNS.
 
Shareholders are encouraged to send any questions for the Chairman to  info@reneuron.com at least 48 hours prior to the meeting. Where appropriate, such questions and answers will be collated and later published, together with full voting details, in the Investor Centre of the Company's website at www.reneuron.com.
 
ENDS
 
Contacts:
 



ReNeuron


www.reneuron.com/investors




Olav Hellebø, Chief Executive Officer 


Via Walbrook PR














Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace


+44 (0)20 7710 7600
 














Allenby Capital Limited (Joint Broker)


+44 (0)20 3328 5656




James Reeve/George Payne (Corporate Finance)








Stefano Aquilino (Sales & Corporate Broking)


















Walbrook PR (Media & Investor Relations) 


+44 (0)20 7933 8780 or reneuron@walbrookpr.com




Paul McManus, Alice Woodings


+44 (0)7980 541 893 / +44 (0)7407 804 654



 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NOADKABDNBKDNFD